NASDAQ$CBUS
Cibus Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Announced financial results for the quarter ended June 30, 2023, and provided a business update.
Cibus reported its second quarter 2023 financial results, highlighting progress on key milestones including the closing of the merger with Calyxt, commercialization of first three trait products, opening of high-throughput trait development facility, and a collaboration agreement with Bayer Ag.
- Closed merger with Calyxt, Inc. on May 31, 2023, establishing a high-throughput plant breeding platform.
- Began commercializing first three trait products by sending customers initial transfers of their elite germplasm with Cibus traits.
- Opened the world’s first stand-alone high-throughput trait development facility for editing plants to support the commercial expansion of the trait business.
- Entered into a collaboration agreement with Bayer Ag to evaluate Cibus’ Trait Machine and capabilities.
Headline financials
Revenue & EPS history
Cibus · Revenue · Quarterly
$197K
Forward guidance
Cibus expects to accomplish several important milestones in the second half of 2023, including validating its Trait Machine process in a customer’s elite soybean germplasm, transferring up to five additional seed company partners its pod shatter reduction trait, initiating field trials in the UK for winter oilseed rape, releasing additional greenhouse and field data associated with its Sclerotinia resistance trait and its HT2 trait, initiating editing for its initial mode of action for nitrogen-use efficiency in canola, and entering into additional breeding collaborations in North America and South America for its HT1 and HT3 traits.
Tailwinds
- Successfully validate its Trait Machine process in a customer’s elite soybean germplasm.
- Begin editing in its soybean platform in 2023.
- Transfer up to five additional seed company partners its pod shatter reduction trait in the customers’ elite germplasm.
- Initiate field trials in the UK for winter oilseed rape.
- Initiate editing for its initial mode of action for nitrogen-use efficiency in canola.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-1.1%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-12.5%
Avg return
30 days after
37%
13 / 35 earnings
Positive
+23.6%
Q4 2019
Best reaction
-25.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -10.3% | -15.2% | |
| Q4 2025 | -16.7% | -24.7% | -56.8% | |
| Q3 2025 | -0.8% | +1.6% | +28.8% | |
| Q2 2025 | -3.5% | -11.6% | -7.5% | |
| Q1 2025 | -7.8% | -8.1% | -29.4% | |
| Q4 2024 | -6.4% | -9.6% | -23.7% | |
| Q3 2024 | +14.5% | +15.2% | -8.9% | |
| Q2 2024 | -9.2% | +2.7% | -42.4% | |
| Q1 2024 | +2.2% | +9.5% | -37.5% | |
| Q4 2023 | -0.7% | +2.2% | +7.4% | |
| Q3 2023 | +17.0% | +5.0% | -8.8% | |
| Q2 2023 | -9.7% | -13.8% | -19.8% | |
| Q1 2023 | -3.6% | -8.3% | -15.8% | |
| Q4 2022 | +1.6% | -0.7% | -21.5% | |
| Q3 2022 | -1.4% | -7.7% | +22.5% | |
| Q2 2022 | +12.4% | +4.3% | -11.6% | |
| Q1 2022 | -17.3% | -27.4% | -60.0% | |
| Q4 2021 | -2.8% | -21.3% | -20.6% | |
| Q3 2021 | -7.4% | -9.0% | -41.9% | |
| Q2 2021 | +12.0% | +15.1% | +19.9% | |
| Q1 2021 | +4.6% | +3.3% | -17.4% | |
| Q4 2020 | -25.1% | -24.7% | -35.6% | |
| Q3 2020 | -1.4% | -4.0% | -44.3% | |
| Q2 2020 | -6.6% | +0.2% | -8.3% | |
| Q1 2020 | -15.0% | -9.4% | +27.9% | |
| Q4 2019 | +23.6% | +22.7% | -10.1% | |
| Q3 2019 | -9.7% | -10.2% | -16.3% | |
| Q2 2019 | +2.7% | -13.1% | -23.9% | |
| Q1 2019 | -3.5% | -6.7% | -9.3% | |
| Q4 2018 | +8.3% | +20.0% | +34.0% | |
| Q3 2018 | -2.9% | -4.9% | -22.1% | |
| Q2 2018 | -0.7% | -3.1% | -10.8% | |
| Q1 2018 | +1.9% | +22.1% | +28.1% | |
| Q4 2017 | +6.4% | +18.8% | +16.9% | |
| Q3 2017 | +7.8% | +8.2% | -2.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro